Overexposure of humans to heavy metals and essential metals poses a significant risk for the development of neurological and neurodevelopmental disorders. The mechanisms through which these metals exert their effects include the generation of reactive oxygen species, mitochondrial dysfunction, activation of inflammatory pathways, and disruption of cellular signaling. The function of glial cells in brain development and in the maintenance of homeostasis cannot be overlooked. The glial cells are particularly susceptible to metal-induced neurotoxicity. Accumulation of metals in the brain promotes microglial activation, triggering inflammatory responses that can coincide with other mechanisms of neurotoxicity, inducing alteration in synaptic transmission, cognitive deficit, and neuronal damage. In this review, we highlighted the role of glial dysfunction in some selected neurodegenerative diseases and neurodevelopmental disorders. We further dive into how exposure to metals such as nickel, manganese, methyl mercury, cadmium, iron, arsenic, and lead affect the functions of the microglia, astrocytes, and oligodendrocytes and the mechanisms through which they exert the effects on the brain in relation to some selected neurodegenerative diseases and neurodevelopmental disorders. Potential therapeutic interventions such as the use of new and improved chelating agents and antioxidant therapies might be a significant approach to alleviating these metal-induced glial perturbations.
The existing literature on neurodegenerative diseases (NDDs) reveals a common pathological feature: the accumulation of misfolded proteins. However, the heterogeneity in disease onset mechanisms and the specific brain regions affected complicates the understanding of the diverse clinical manifestations of individual NDDs. Dementia, a hallmark symptom across various NDDs, serves as a multifaceted denominator, contributing to the clinical manifestations of these disorders. There is a compelling hypothesis that therapeutic strategies capable of mitigating misfolded protein accumulation and disrupting ongoing pathogenic processes may slow or even halt disease progression. Recent research has linked disease‐associated microglia to their transition into a senescent state—characterized by irreversible cell cycle arrest—in aging populations and NDDs. Although senescent microglia are consistently observed in NDDs, few studies have utilized animal models to explore their role in disease pathology. Emerging evidence from experimental rat models suggests that disease‐associated microglia exhibit characteristics of senescence, indicating that deeper exploration of microglial senescence could enhance our understanding of NDD pathogenesis and reveal novel therapeutic targets. This review underscores the importance of investigating microglial senescence and its potential contributions to the pathophysiology of NDDs, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Additionally, it highlights the potential of targeting microglial senescence through iron chelation and senolytic therapies as innovative approaches for treating age‐related NDDs.
Recent evidence suggests a more important role of the gut microbiota in neurodegenerative diseases (NDDs) given its relationship through the microbiota‐gut‐brain as an active communication system aiding in maintaining homeostasis between the brain and the gut. This review focuses on how modulation of gut microbiota can serves as a therapeutic strategy for NDDs, emphasizing the neuroprotective effects of probiotics. Probiotics are live microorganisms that confer health benefits, and their interaction with gut‐microbiota influences neurogenesis, neurotransmitter regulation, and neuroinflammation. Recent advancements, including germ‐free animal models, fecal microbiota transplantation (FMT), and diverse probiotic strains, have revealed the underlying mechanisms linking gut health to brain function. Notably, several Lactobacillus and Bifidobacterium species have been shown to exert neuroprotective effects via the upregulation of neurotrophic factors such as brain‐derived neurotrophic factor and enhancing mitochondrial function through reducing the impacts of oxidative stress. Interestingly, FMT has exhibited a degree of success in overcoming cognitive impairment and motor deficits in preclinical studies and clinical trials. However, further research is warranted to explore its therapeutic potential in humans. Overall, this review highlights the significant role of gut microbiota in NDDs and advocates for gut‐targeted interventions as innovative approaches to mitigate these diseases.
Parkinson’s disease (PD) or Parkinsonism is an age-related progressive neurological disorder because of the deterioration of the nerve cells inside the substantia nigra, and it is characterized by three cardinal signs: rigidity, resting tremor, and bradykinesia. The major aim of therapy is to control the disorder’s signs and symptoms, delay the progression of the disease, and enhance the affected person’s quality of life (QoL). This can be achieved by the use of medication (drugs) and surgery. Pharmacotherapy of PD refers to utilizing drugs to replace, mimic, or potentiate the action of depleted endogenous brain’s dopamine and aims at delaying the progression of the disorder, reducing the drugs’ adverse effects, and improving the patient’s QoL. Drugs employed in the treatment of PD are broadly divided into two categories: dopaminergic system-acting drugs and cholinergic system-acting drugs. However, levodopa remains the first choice drug for the management of Parkinsonism to date. Despite the availability of drugs for the management of Parkinsonism, the progressive nature of the disorder has resulted in their failure to confer lasting therapeutic efficacy as the majority of the features of the disease become resistant to these drugs. Also, severe adverse effects with little or lack of enhancement in the patient’s QoL often accompany the use of multiple drug regimens, hence limiting the attainment of the overall goal of pharmacotherapy. <!----> <!----> <!----> <!---->
Parkinson’s disease (PD), also known as Parkinsonism, is a neurological condition that mostly, but not solely, impairs movement control. It is distinguished by an increased deterioration and loss of dopamine-producing neurons in the substantia nigra area of the brain. The exact aetiology of PD is complicated and multifaceted. It is considered to comprise a blend of genetic vulnerability and environmental variables that contribute to the development of the condition. Some of the important reasons include heredity, the pile-up of abnormal alpha-synuclein proteins in the brain and enteric nervous systems, heavy metal neurotoxicity, head trauma, and so on. Over the years, the diagnosis of PD has mostly hinged on the clinical triad of its movement-related symptoms: tremor, rigidity, and bradycardia. Though these symptoms are not prodromal of PD, they are often detected in the extremely severe phase of the illness when therapies and treatments are no longer highly effective. Therefore, this review focuses on the need for understanding the prodromal biomarkers associated with PD, such as non-motor biomarkers, biochemical biomarkers, and inflammatory biomarkers, as well as advances in neuroimaging biomarkers, in order to facilitate new diagnostic methods other than the normal motor symptoms to aid early diagnosis and responsive therapies and treatments of the disease. Some new discoveries, such as that of distinct neural networks and pathways of the illness, combination biomarkers, and salivary gland biopsy, are promising and could assist to quickly detect the condition. <!----> <!----> <!----> <!---->